Amzeeq generic
Amzeeq is a topical acne treatment medication owned by Journey. It contains the active ingredient minocycline hydrochloride and was first authorized for market use on 18 October, 2019. Amzeeq holds a total of 12 patents with none expired.
When will Amzeeq generic be available?
The last patent of Amzeeq is set to expire on 8 September, 2037, after which generics of Amzeeq can potentially be released. This date may account for a possible Para IV filing which challenges the patent validity.
Amzeeq uses
Amzeeq is primarily used for the treatment of non-nodular acne vulgaris. Its active ingredient, minocycline hydrochloride, helps in reducing inflammation and bacterial growth that are often associated with acne.
Amzeeq patent expiration
Amzeeq holds a total of 12 patents, the latest of which, focused on compositions and methods for treating rosacea and acne, expires on 8 September, 2037. For more information regarding when an Amzeeq generic may become available, see patent details below. Below are the details of the patent: